MedTrace Logo

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06630247 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-06-25

No results posted yet for this study

Summary

The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.

Conditions

  • Solid Cancers
  • Solid Tumor Cancer
  • Solid Tumor Malignancy
  • Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
  • Metastatic Solid Tumor
  • Locally Advanced Solid Tumor
  • Urothelial Cancer of Renal Pelvis

Interventions

DRUG

XL495

oral doses of XL495

DRUG

ADC cytotoxic agents

intravenous infusion of anti-cancer combination agent

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-17
Primary Completion
2025-05-07
Completion
2025-05-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06630247 on ClinicalTrials.gov